Neutrophil Extracellular Traps (NETs) and Covid-19: A new frontiers for therapeutic modality
Abstract Coronavirus disease 2019 (Covid-19) is a worldwide infectious disease caused by
severe acute respiratory coronavirus 2 (SARS-CoV-2). In severe SARS-CoV-2 infection …
severe acute respiratory coronavirus 2 (SARS-CoV-2). In severe SARS-CoV-2 infection …
An updated review of computer‐aided drug design and its application to COVID‐19
The recent outbreak of the deadly coronavirus disease 19 (COVID‐19) pandemic poses
serious health concerns around the world. The lack of approved drugs or vaccines continues …
serious health concerns around the world. The lack of approved drugs or vaccines continues …
[HTML][HTML] Potential resistance of SARS-CoV-2 main protease (Mpro) against protease inhibitors: lessons learned from HIV-1 protease
Coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome 2
(SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of …
(SARS-CoV-2), has been one of the most devastating pandemics of recent times. The lack of …
Drug targeting Nsp1-ribosomal complex shows antiviral activity against SARS-CoV-2
Abstract The SARS-CoV-2 non-structural protein 1 (Nsp1) contains an N-terminal domain
and C-terminal helices connected by a short linker region. The C-terminal helices of Nsp1 …
and C-terminal helices connected by a short linker region. The C-terminal helices of Nsp1 …
Structure-based design of a dual-targeted covalent inhibitor against papain-like and main proteases of SARS-CoV-2
W Yu, Y Zhao, H Ye, N Wu, Y Liao… - Journal of Medicinal …, 2022 - ACS Publications
The two proteases, PLpro and Mpro, of SARS-CoV-2 are essential for replication of the virus.
Using a structure-based co-pharmacophore screening approach, we developed a novel …
Using a structure-based co-pharmacophore screening approach, we developed a novel …
[HTML][HTML] A dual pharmacological strategy against COVID-19: The therapeutic potential of metformin and atorvastatin
LA De Jesús-González, RM Del Ángel… - Microorganisms, 2024 - mdpi.com
Metformin (MET) and atorvastatin (ATO) are promising treatments for COVID-19. This review
explores the potential of MET and ATO, commonly prescribed for diabetes and dyslipidemia …
explores the potential of MET and ATO, commonly prescribed for diabetes and dyslipidemia …
[HTML][HTML] Targeting NMDA receptor in Alzheimer's disease: identifying novel inhibitors using computational approaches
AJ Siddiqui, R Badraoui, S Jahan… - Frontiers in …, 2023 - frontiersin.org
The glutamate-gated ion channels known as N-methyl-d-aspartate receptors (NMDARs) are
important for both normal and pathological brain function. Subunit-selective antagonists …
important for both normal and pathological brain function. Subunit-selective antagonists …
[HTML][HTML] Synergistic interactions of repurposed drugs that inhibit Nsp1, a major virulence factor for COVID-19
HT Kao, A Orry, MG Palfreyman, B Porton - Scientific Reports, 2022 - nature.com
Nsp1 is one of the first proteins expressed from the SARS-CoV-2 genome and is a major
virulence factor for COVID-19. A rapid multiplexed assay for detecting the action of Nsp1 …
virulence factor for COVID-19. A rapid multiplexed assay for detecting the action of Nsp1 …
[HTML][HTML] Nobiletin as a neuroprotectant against NMDA receptors: an in silico approach
Excitotoxicity is a type of neurodegenerative disorder. It caused by excessive glutamate
receptor activation, which leads to neuronal malfunction and fatality. The N-methyl-D …
receptor activation, which leads to neuronal malfunction and fatality. The N-methyl-D …
[HTML][HTML] Targeting SARS-CoV-2 nsp13 helicase and assessment of druggability pockets: identification of two potent inhibitors by a multi-site in silico drug repurposing …
The SARS-CoV-2 non-structural protein 13 (nsp13) helicase is an essential enzyme for viral
replication and has been identified as an attractive target for the development of new …
replication and has been identified as an attractive target for the development of new …